Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense related to clinical trial failures.
We do this by generating highly valuable, predictive human data in advance of clinical trials, ensuring the selection of the most effective and safest drugs. Through proprietary technology based on the use of human donor organs and tissues, we study ex vivo human responses to drugs and further investigate the molecular and functional basis of relevant human physiology.
Our research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease and neurodegeneration. In partnership with Fortune 500 pharmaceutical companies, contract research organizations and universities, our mission is to develop therapeutic advancements to help patients live longer, healthier and more productive lives.
AnaBios products and services are marketed directly, as well as through distributors and partners worldwide. AnaBios also drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry and academia.